ITMCTR2023000033尚未招募1 期
Clinical observation on the treatment of type IIIB prostatitis by combining YiqiHuoXueTuoDu Formula with modified abdominal and anal retracting and lifting exercise
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 50（—）
- 性别
- Male
入选标准
- •1. Meanwhile, it meets the requirements of ?B prostatitis diagnostic standard of modern medicine and Chinese medicine;
- •2. Male patients aged between 18 and 50 years old;
- •3. not undergoing prostatitis-related treatment within two weeks prior to enrolment;
- •4. Patients who voluntarily joined the study, had good compliance and signed the informed consent document.
排除标准
- •1. Persons with a history of allergy to the test drug or low blood pressure and intolerance to the drug;
- •2. those with severe primary cardiovascular lesions, liver lesions, renal lesions, haematological lesions, pulmonary diseases, or serious diseases affecting their survival, such as tumours or AIDS, which are considered by the investigator to be inappropriate for enrolment. Liver function ALT, AST, renal function BUN more than 50% of the upper limit of normal value, renal function Cr more than the upper limit of normal value, will not be enrolled.
- •3. Those with severe obstructive diseases of the urinary tract that require surgical treatment;
- •4. Combined with severe mental and spiritual changes that make it difficult to communicate and cooperate;
- •5. Patients with other organic diseases of the prostate, such as prostate tumour, benign prostatic hyperplasia, etc.
研究者
相似试验
进行中（未招募）
不适用
A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and RituximabTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphomaEUCTR2005-000693-45-ITG.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
进行中（未招募）
不适用
Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing erlotinib or gefitinib - NDPatients with confirmed diagnosis of NSCLCMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2007-005983-28-ITBOEHRINGER ING.480
进行中（未招募）
不适用
Phase IIb/III randomized, double-blind trial of BIBW 2992 plus bestsupportive care (BSC) versus placebo plus BSC in non small cell lungcancer patients failing erlotinib or gefitinib - Phase IIb/III NSCLC Iressa/Tarceva FailuresPatients with confirmed diagnosis of non-small cell lung cancer whose disease progressed after at least one but not more than two lines of cytotoxic chemotherapy of which one must have been a platinum containing regimen with erlotinib or gefitinib for at least 12 weeks.EUCTR2007-005983-28-FRBoehringer Ingelheim France400
进行中（未招募）
1 期
Phase IIb/III randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non small cell lung cancer patients failing erlotinib or gefitinib - Phase IIb/III NSCLC Iressa/Tarceva FailuresEUCTR2007-005983-28-GBBoehringer Ingelheim Limited698
进行中（未招募）
不适用
Phase IIb/III randomized, double-blind trial of BIBW 2992 plus bestsupportive care (BSC) versus placebo plus BSC in non small cell lungcancer patients failing erlotinib or gefitinib - Phase IIb/III NSCLC Iressa/Tarceva FailuresPatients with confirmed diagnosis of non-small cell lung cancer whose disease progressed after at least one but not more than two lines of cytotoxic chemotherapy of which one must have been a platinum containing regimen with erlotinib or gefitinib for at least 12 weeks.MedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2007-005983-28-NLBoehringer Ingelheim bv560